1. A novel small-molecule inhibitor of IL-6 signalling
- Author
-
Daniel A. Morgenstern, David E. Thurston, Samantha L. Kaye, Shozeb Haider, B. Piku Basu, Stephen Neidle, Samantha Essex, Khondaker M. Rahman, Fyeza Hasan, John Anderson, Andrew F. Wilderspin, Giovanna Zinzalla, Mohammad Rashedul Haque, Dyeison Antonow, and Jonathan Palmer
- Subjects
STAT3 Transcription Factor ,Pyrrolidines ,Clinical Biochemistry ,Pharmaceutical Science ,Breast Neoplasms ,Biochemistry ,Small Molecule Libraries ,HeLa ,Structure-Activity Relationship ,Cell Line, Tumor ,Drug Discovery ,Humans ,Sulfones ,Phosphorylation ,STAT3 ,Molecular Biology ,biology ,Interleukin-6 ,Chemistry ,Organic Chemistry ,Biological activity ,Cytostatic Agents ,biology.organism_classification ,Small molecule ,Docking (molecular) ,Cell culture ,biology.protein ,Molecular Medicine ,Female ,Signal transduction ,HeLa Cells ,Signal Transduction - Abstract
A small library of pyrrolidinesulphonylaryl molecules has been synthesized via an efficient 4-step route, and members evaluated for their ability to inhibit IL-6 signalling. One molecule (6a) was found to have promising activity against IL-6/STAT3 signalling at the low micromolar level, and to selectively inhibit phosphorylation of STAT3 (but not STAT1) in IL-6 stimulated MDA-MB-231 breast cancer and HeLa cell lines. It was also selectively cytostatic in MDA-MB-231 (STAT3-dependent) versus A4 (STAT3-null) cells suggesting STAT3-specific inhibitory properties.
- Published
- 2010
- Full Text
- View/download PDF